Yoshiaki Fujimori - Boston Scientific Independent Director

<div class='logoBackup' style='background:#754DEB;color: white;font-size:3em;;'>BSX</div>
BSX -- USA Stock  

Trending

  Director
Mr. Yoshiaki Fujimori is Independent Director of the Company. Mr. Fujimori is currently an adviser to the LIXIL Group Corporationrationration, a position he has held since June 2016, and was the President and Chief Executive Officer of the LIXIL Group Corporationrationration from August 2011 to June 2016. Prior to joining LIXIL, he was Chairman, President and Chief Executive Officer of GE Japan from January 2008 to June 2011. In his 25 years at GE, beginning in October 1986, he held a variety of positions including Senior Vice President and Chief Executive Officer of a number of Asian and global business divisions, including Medical Systems, Plastics, and Capital. Mr. Fujimori also served as a member of the GE Corporationrationrate Executive Council from 2001 to 2010. He formerly served as a Director of the Japan Construction Material Housing Equipment Industries Federation and Tokyo Electric Power Company Holdings.
Age: 67  Director Since 2016      
508 683-4000  www.bostonscientific.com
Fujimori serves as an external director of Tokyo Electric Power Company, a role he has held since June 2012. He is also an external director for Takeda Pharmaceutical Company Limited. He previously served as chairman of the Japan Construction Material & Housing Equipment Industries Federation. He received his bachelor?s degree in petroleum engineering from the University of Tokyo and his master?s degree from Carnegie Mellon Graduate School of Business, where he serves as a lifetime member of the Board of Trustees.

Management Efficiency

The company has Return on Asset of 0.04 % which means that on every $100 spent on asset it made $0.04 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.1 % implying that it generated $0.1 on every 100 dollars invested.
The company has 9.8 B in debt with debt to equity (D/E) ratio of 103.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Boston Scientific has Current Ratio of 1.28 demonstrating that it is in a questionable position to pay out its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Edward SchutterEstablishment Labs Holdings
2016
William LinkEdwards Lifesciences Corporatio
Ruediger NaumannEtienneENCISION INC
2008
William EcklesElectromed
2011
Sean CloskeyESCALON MEDICAL CORP
2013
Mitchell QuainDigirad Corporation
2019
Larry BeardallDynatronics Corporation
1992
Brian LarkinDynatronics Corporation
2015
Robrecht MichielsEDAP TMS SA
2009
Wesley SchackEdwards Lifesciences Corporatio
2018
Charles GillmanDigirad Corporation
2012
David NewtonENCISION INC
1991
Scott WardDynatronics Corporation
2013
William LinkSecond Sight Medical Products
Lisa ColleranEstablishment Labs Holdings
2015
Steven LorangerEdwards Lifesciences Corporatio
2016
Vern KornelsenENCISION INC
1998
Fred ChoateESCALON MEDICAL CORP
2005
Leslie HeiszEdwards Lifesciences Corporatio
2016
Stan EricksonElectromed
2014
Gregg WilliamsSecond Sight Medical Products
2018

Entity Summary

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts. Boston Scientific operates under Medical Devices classification in USA and is traded on BATS Exchange. It employs 32000 people.Boston Scientific Corporation (BSX) is traded on BATS Exchange in USA. It is located in 300 Boston Scientific Way, Marlborough, MA 01752-1234, United States and employs 32,000 people. Boston Scientific is listed under Medical Equipment category by Fama And French industry classification.

Boston Scientific Leadership Team

Edward Ludwig, Lead Independent Director
Donna James, Independent Director
Stephen MacMillan, Independent Director
Michael Mahoney, Chairman of the Board, President, Chief Executive Officer
Kevin Ballinger, Executive Vice President and Global President - Interventional Cardiology
Desiree RallsMorrison, Senior Vice President General Counsel, Corporate Secretary
Keith Dawkins, Global Chief Medical Officer, Executive Vice President
Maulik Nanavaty, Senior Vice President and President - Neuromodulation
Ian Meredith, Executive Vice President Global Chief Medical Officer
David Pierce, Executive Vice President and President - MedSurg
Supratim Bose, Executive VP and President of Asia-Pac, Middle East and Africa
Ellen Zane, Independent Director
Joseph Fitzgerald, Executive Vice President and President - Rhythm Management
Warren Wang, Senior Vice President and President - Asia Pacific
Timothy Pratt, Chief Admin. Officer, Executive VP, General Counsel and Secretary
Eric Thepaut, Senior Vice President and President, Europe, Middle East and Africa
Daniel Brennan, CFO, Principal Accounting Officer and Executive VP
Kristina Johnson, Independent Director
Nelda Connors, Independent Director
Wendy Carruthers, Senior Vice President - Human Resources
Peter Nicholas, Co-Founder and Chairman of The Board
John Sorenson, Senior Vice President - Manufacturing and Supply Chain
Arthur Butcher, Senior Vice President and President - Endoscopy
Edward Mackey, Executive Vice President - Operations
Ernest Mario, Independent Director
Karen Prange, Senior Vice President and President - Urology & Women's Health
N Nicholas, Independent Director
Charles Dockendorff, Independent Director
John Sununu, Independent Director
Michael Phalen, Executive Vice President and President - MedSurg
Jeffrey Mirviss, Senior Vice President and President - Peripheral Interventions
Yoshiaki Fujimori, Independent Director
David Roux, Independent Director
Susan Lisa, VP, Investor Relations
Jonathan Monson, Chief Accounting Officer, Vice President Global Controller

Stock Performance Indicators

Current Sentiment - BSX

Boston Scientific Investor Sentiment

Greater number of Macroaxis users are currently bullish on Boston Scientific Corporation. What is your opinion about investing in Boston Scientific Corporation? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Boston Scientific Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Boston Scientific and Edwards Lifesciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.